Adaptive Biotechnologies is trading 4.45% down at $24.07 amid broader market weakness, though no definitive catalyst has been identified.
- The Dow Jones is down 0.65% amid geopolitical, oil-price, and hawkish Federal Reserve concerns.
- No fresh August 31, 2026 company announcement or confirmed analyst downgrade was found; the latest release was its July 29, 2026 second-quarter report.
- Recent insider sales, including director Katey Einterz Owen disclosed August 28, may weigh on sentiment but predate this session.